277 related articles for article (PubMed ID: 16027729)
1. cFos is critical for MCF-7 breast cancer cell growth.
Lu C; Shen Q; DuPré E; Kim H; Hilsenbeck S; Brown PH
Oncogene; 2005 Sep; 24(43):6516-24. PubMed ID: 16027729
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.
Liu Y; Ludes-Meyers J; Zhang Y; Munoz-Medellin D; Kim HT; Lu C; Ge G; Schiff R; Hilsenbeck SG; Osborne CK; Brown PH
Oncogene; 2002 Oct; 21(50):7680-9. PubMed ID: 12400010
[TBL] [Abstract][Full Text] [Related]
3. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors.
Shen Q; Uray IP; Li Y; Krisko TI; Strecker TE; Kim HT; Brown PH
Oncogene; 2008 Jan; 27(3):366-77. PubMed ID: 17637753
[TBL] [Abstract][Full Text] [Related]
4. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
Liu Y; Lu C; Shen Q; Munoz-Medellin D; Kim H; Brown PH
Oncogene; 2004 Oct; 23(50):8238-46. PubMed ID: 15378019
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of a dominant-negative mutant of c-Jun.
Brown PH; Chen TK; Birrer MJ
Oncogene; 1994 Mar; 9(3):791-9. PubMed ID: 8108121
[TBL] [Abstract][Full Text] [Related]
6. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
7. Activation and inhibition of the AP-1 complex in human breast cancer cells.
Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
[TBL] [Abstract][Full Text] [Related]
8. AP-1 blockade inhibits the growth of normal and malignant breast cells.
Ludes-Meyers JH; Liu Y; Muñoz-Medellin D; Hilsenbeck SG; Brown PH
Oncogene; 2001 May; 20(22):2771-80. PubMed ID: 11420689
[TBL] [Abstract][Full Text] [Related]
9. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
Suzukawa K; Colburn NH
Oncogene; 2002 Mar; 21(14):2181-90. PubMed ID: 11948401
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of AP-1 suppresses cervical cancer cell proliferation and is associated with p21 expression.
Maritz MF; van der Watt PJ; Holderness N; Birrer MJ; Leaner VD
Biol Chem; 2011 May; 392(5):439-48. PubMed ID: 21417953
[TBL] [Abstract][Full Text] [Related]
11. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.
Smith LM; Wise SC; Hendricks DT; Sabichi AL; Bos T; Reddy P; Brown PH; Birrer MJ
Oncogene; 1999 Oct; 18(44):6063-70. PubMed ID: 10557095
[TBL] [Abstract][Full Text] [Related]
12. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells.
Zhao B; Yu W; Qian M; Simmons-Menchaca M; Brown P; Birrer MJ; Sanders BG; Kline K
Mol Carcinog; 1997 Jul; 19(3):180-90. PubMed ID: 9254885
[TBL] [Abstract][Full Text] [Related]
13. Selectional and mutational scope of peptides sequestering the Jun-Fos coiled-coil domain.
Hagemann UB; Mason JM; Müller KM; Arndt KM
J Mol Biol; 2008 Aug; 381(1):73-88. PubMed ID: 18586270
[TBL] [Abstract][Full Text] [Related]
14. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
[TBL] [Abstract][Full Text] [Related]
15. A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen-activated protein kinase pathway to activate c-Jun N-terminal kinase and a functional AP-1 containing c-Jun and c-Fos proteins in mouse NB2a cells.
Adams DS; Hasson B; Boyer-Boiteau A; El-Khishin A; Shashoua VE
J Neurosci Res; 2003 May; 72(3):405-16. PubMed ID: 12692907
[TBL] [Abstract][Full Text] [Related]
16. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies.
Brown PH; Kim SH; Wise SC; Sabichi AL; Birrer MJ
Cell Growth Differ; 1996 Aug; 7(8):1013-21. PubMed ID: 8853897
[TBL] [Abstract][Full Text] [Related]
17. Bovine dialyzable leukocyte extract modulates AP-1 DNA-binding activity and nuclear transcription factor expression in MCF-7 breast cancer cells.
Mendoza-Gamboa E; Franco-Molina MA; Zapata-Benavides P; Castillo-Tello P; Vera-García ME; Tamez-Guerra RS; Rodríguez-Padilla C
Cytotherapy; 2008; 10(2):212-9. PubMed ID: 18368600
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation.
Bossis G; Malnou CE; Farras R; Andermarcher E; Hipskind R; Rodriguez M; Schmidt D; Muller S; Jariel-Encontre I; Piechaczyk M
Mol Cell Biol; 2005 Aug; 25(16):6964-79. PubMed ID: 16055710
[TBL] [Abstract][Full Text] [Related]
19. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
Grant S; Freemerman AJ; Birrer MJ; Martin HA; Turner AJ; Szabo E; Chelliah J; Jarvis WD
Cell Growth Differ; 1996 May; 7(5):603-13. PubMed ID: 8732670
[TBL] [Abstract][Full Text] [Related]
20. Mitogen activated protein kinase-dependent activation of c-Jun and c-Fos is required for neuronal differentiation but not for growth and stress response in PC12 cells.
Eriksson M; Taskinen M; Leppä S
J Cell Physiol; 2007 Feb; 210(2):538-48. PubMed ID: 17111371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
